Trial document

PLEASE NOTE:
This study has been imported from ClinicalTrials.gov without additional data checks.

drksid header

DRKS-ID: DRKS00005837

Trial Description

start of 1:1-Block title

Title

Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

EFACTS

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

This is a multi-centre, multi-national, prospective, observational study of Friedreich's
Ataxia (FRDA) with a control group to:

- obtain natural history data on individuals affected by FRDA

- relate clinical assessments and results from proteomic analyses

- expedite identification and recruitment of participants for clinical trials

- develop and validate sensitive and reliable outcome measures for detecting onset and
change over the natural course of FRDA which may also be potential outcome measures for
use in future clinical trials and clinical care

- plan for future research studies

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The EFACTS patient registry integrates prospectively and systematically collected clinical
research data (e.g. clinical tests, demographical characteristics) with access to biological
specimens (e.g. blood, urine) obtained from individuals with genetically confirmed FRDA and
unrelated control research participants.

The EFACTS patient registry is a 4-year study and eligible subjects are assessed at annual
study visits on the clinical symptoms and signs of the disease. At each study visit, general
clinical, motor function, cognitive, and Quality of Life assessments are administered. In
addition, participants are providing bio samples for the purposes of genetic testing and for
research to identify valuable biomarkers of FRDA. Biological specimens and clinical data are
made available to qualified scientists within the EFACTS network whose projects are reviewed
and approved by the EFACTS Steering Committee. Research projects should aim to advance
scientific knowledge towards establishing clinically effective treatments that delay onset
and/or slow the progression of the disease.

end of 1:1-Block scientific synopsis

start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data

start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00005837
Date of Registration in DRKS: 2015/01/19
Date of Registration in Partner Registry or other Primary Registry: 2014/02/19
Investigator Sponsored/Initiated Trial (IST/IIT): yes
Ethics Approval/Approval of the Ethics Committee: [---]*
(leading) Ethics Committee No.: [---]*

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

Primary Registry-ID: NCT02069509 (ClinicalTrials.gov)
Sponsor-ID: HEALTH-F2-2010- 242193 (European Friedreich's Ataxia Consortium for Translational Studies)

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

Free text: Friedreich's Ataxia
ICD10: G11.1 - Early-onset cerebellar ataxia

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

[---]*

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Non-interventional
Study Type Non-Interventional: Observational study
Allocation: [---]*
Blinding: [---]*
Who is blinded: [---]*
Control: [---]*
Purpose: [---]*
Assignment: [---]*
Phase: N/A
Off-label Drug use: [---]*

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

- Disease progression as assessed by clinical examination; time frame: Participants are followed for a max. of 4 years with annual assessments

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

[---]*

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

AT: Austria
BE: Belgium
FR: France
DE: Germany
IT: Italy
ES: Spain
UK: United Kingdom

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

University Hospital Aachen, Dept. of Neurology, Aachen
University Hospital Bonn, Dept. of Neurology, Bonn
Philipps University Marburg, Dept. of Neurology, Marburg
University of Munich, Dept. of Neurology, Munich
University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, Tübingen

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: [---]*
(Anticipated or Actual) Date of First Enrollment: 2010/05/31
Target Sample Size: 650
Monocenter/Multicenter trial: Multicenter trial
National/International: International

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: no minimum age
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion Criteria:

- Genetic diagnosis of FRDA

- For control research participants: genetically confirmed absence of FRDA

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

[---]*

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- European Friedreich's Ataxia Consortium for Translational Studies
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- University Hospital Aachen, Dept. of Neurology
- Jörg B. Schulz
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Jörg B. Schulz, MD
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: 0049-241-80-89600
- Fax: [---]*
- E-mail: jschulz at ukaachen.de
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

[---]*
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting ongoing
Study Closing (LPLV): [---]*

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

Further trial documents: EFACTS Registry

end of 1:n-Block publications

The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .

Translation on version: 1
Last processed date by ClinicalTrials.gov: 2014/02/23

* This entry means the parameter is not applicable or has not been set.